The liquid biopsy was valued at US$ 3,861.49million in 2019 and is projected to reach US$ 8,123.85 million by 2027; it is expected to grow at a CAGR of 9.9% from 2020 to 2027.
The growing prevalence of cancer is a driving factor for the growth of global liquid biopsy market. However, low sensitivity of liquid biopsy is likely to restrain the growth of the market during the forecast period.
Liquid biopsy is a noninvasive diagnostic test that identifies various types of cancer. The increasing prevalence of cancer among population is leading to the growth of liquid biopsy market across the world. For instance, in Canada, cancer is the leading cause of death among population and it is witnessed to be a second-leading cause after heart diseases in the US. As per the American Cancer Society, Inc, approximately, 1.9 million new cancer cases and 693,000 cancer deaths were recorded in 2018, in Northern America. Prostate cancers are the most commonly diagnosed cancers among males in North America; however, breast cancers remains leading in females. Additionally, lung cancer remains the most common cause of death in both sexes. It is estimated that the number of new cancer cases is accounted for 439.2 per 100,000 men and women every year.
According to the National Health Profile, the cases of common cancers, including cervical, oral, and breast cancers have increased by 324%in India between 2017 and 2018. Additionally, the total number of patients visiting Non Communicable Diseases (NCD) clinics have doubled from 2017 to 2018, which is recorded as 3.5 crore to 6.6 crore respectively. Rapid change in lifestyle and increasing consumption of alcohol and tobacco products are the factors increasing the incidences of cancer among the population.
The global liquid biopsy market is segmented into product & services, sample, circulating biomarker, application, and end user. The circulating biomarker is further segmented into circulating tumor cells (CTC), exosomes, and free nucleic acid. The circulating tumor cells (CTC) segment held the largest share of the market in 2019 and is anticipated to register the highest CAGR in the market during the forecast period. Based on application, the liquid biopsy market is segmented into oncology, noninvasive prenatal testing (NIPT), transplant diagnostics, and other applications. The oncology segment held the largest share in 2019 of the market; moreover, noninvasive prenatal testing (NIPT) is expected to register fastest growth. Furthermore, based on end user, the liquid biopsy market is segmented into hospitals, reference laboratories, academic & research institutes, and other end users. Hospitals segment is expected to remain dominant during the forecast period.
Cancer Center Amsterdam, Food and Drug Administration, World Health Organization (WHO), Kidney Disease Improving Global Outcomes, and International Diabetes Federation are some of the essential primary and secondary sources included in the report.
Reasons to Buy
The growing prevalence of cancer is a driving factor for the growth of global liquid biopsy market. However, low sensitivity of liquid biopsy is likely to restrain the growth of the market during the forecast period.
Liquid biopsy is a noninvasive diagnostic test that identifies various types of cancer. The increasing prevalence of cancer among population is leading to the growth of liquid biopsy market across the world. For instance, in Canada, cancer is the leading cause of death among population and it is witnessed to be a second-leading cause after heart diseases in the US. As per the American Cancer Society, Inc, approximately, 1.9 million new cancer cases and 693,000 cancer deaths were recorded in 2018, in Northern America. Prostate cancers are the most commonly diagnosed cancers among males in North America; however, breast cancers remains leading in females. Additionally, lung cancer remains the most common cause of death in both sexes. It is estimated that the number of new cancer cases is accounted for 439.2 per 100,000 men and women every year.
According to the National Health Profile, the cases of common cancers, including cervical, oral, and breast cancers have increased by 324%in India between 2017 and 2018. Additionally, the total number of patients visiting Non Communicable Diseases (NCD) clinics have doubled from 2017 to 2018, which is recorded as 3.5 crore to 6.6 crore respectively. Rapid change in lifestyle and increasing consumption of alcohol and tobacco products are the factors increasing the incidences of cancer among the population.
The global liquid biopsy market is segmented into product & services, sample, circulating biomarker, application, and end user. The circulating biomarker is further segmented into circulating tumor cells (CTC), exosomes, and free nucleic acid. The circulating tumor cells (CTC) segment held the largest share of the market in 2019 and is anticipated to register the highest CAGR in the market during the forecast period. Based on application, the liquid biopsy market is segmented into oncology, noninvasive prenatal testing (NIPT), transplant diagnostics, and other applications. The oncology segment held the largest share in 2019 of the market; moreover, noninvasive prenatal testing (NIPT) is expected to register fastest growth. Furthermore, based on end user, the liquid biopsy market is segmented into hospitals, reference laboratories, academic & research institutes, and other end users. Hospitals segment is expected to remain dominant during the forecast period.
Cancer Center Amsterdam, Food and Drug Administration, World Health Organization (WHO), Kidney Disease Improving Global Outcomes, and International Diabetes Federation are some of the essential primary and secondary sources included in the report.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the liquid biopsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global breast cancer screening market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. Liquid Biopsy - Market Landscape
5. Liquid biopsy- Key Market Dynamics
6. Liquid Biopsy Market - Global Analysis
7. Liquid Biopsy Market Analysis - By Product & Services
8. Liquid Biopsy Market Analysis - By Sample
9. Liquid Biopsy Market Analysis - By Circulating Biomarker
10. Liquid Biopsy Market Analysis - By Application
11. Liquid Biopsy Market Analysis - By End User
12. Liquid Biopsy Market - Geographic Analysis
13. Impact Of COVID-19 Pandemic On Global Liquid Biopsy Market
14. Liquid Biopsy Market -Industry Landscape
15. Liquid Biopsy Market, Key Company Profiles
16. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biocept, Inc
- Bio-Rad Laboratories Inc
- LungLife AI, Inc
- Exosome Diagnostics
- F. Hoffmann-la Roche ltd
- Exact Sciences Corporation
- Inivata Ltd
- MDxHealth
- Qiagen
- Thermo Fisher Scientific Inc.
